References
- Peris K, Fargnoli MC, Garbe C, et al. Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines. Eur J Cancer. 2019;118:10–34. doi: 10.1016/j.ejca.2019.06.003
- Asgari MM, Moffet HH, Ray GT, et al. Trends in basal cell carcinoma incidence and identification of high-risk subgroups, 1998-2012. JAMA Dermatol. 2015;151(9):976–981. doi: 10.1001/jamadermatol.2015.1188
- Perera E, Gnaneswaran N, Staines C, et al. Incidence and prevalence of non-melanoma skin cancer in Australia: a systematic review. Australas J Dermatol. 2015;56(4):258–267. doi: 10.1111/ajd.12282
- Kim DP, Kus KJB, Ruiz E. Basal cell carcinoma review. Hematol Oncol Clin North Am. 2019;33(1):13–24. doi: 10.1016/j.hoc.2018.09.004
- Villani A, Potestio L, Fabbrocini G, et al. New emerging treatment options for advanced basal cell carcinoma and squamous cell carcinoma. Adv Ther. 2022;39(3):1164–1178. doi: 10.1007/s12325-022-02044-1
- Herms F, Basset-Seguin N. Emerging drugs for the treatment of basal cell carcinoma. Expert Opin Emerg Drugs. 2021;26(1):17–26. doi: 10.1080/14728214.2021.1873949
- Marzuka AG, Book SE. Basal cell carcinoma: pathogenesis, epidemiology, clinical features, diagnosis, histopathology, and management. Yale J Biol Med. 2015;88(2):167–179.
- Hernandez LE, Mohsin N, Levin N, et al. Basal cell carcinoma: an updated review of pathogenesis and treatment options. Dermatol Ther. 2022;35(6):e15501. doi: 10.1111/dth.15501
- Villani A, Fabbrocini G, Costa C, et al. Sonidegib with and without adjunctive treatment for locally advanced basal cell carcinomas. Oncology. 2022;27(6):e533. doi: 10.1093/oncolo/oyac063
- Peris K, Fargnoli MC, Kaufmann R, et al. European consensus-based interdisciplinary guideline for diagnosis and treatment of basal cell carcinoma-update 2023. Eur J Cancer. 2023;192:113254. doi: 10.1016/j.ejca.2023.113254
- Trakatelli M, Morton C, Nagore E, et al. Update of the European guidelines for basal cell carcinoma management. Eur J Dermatol. 2014;24(3):312–329. doi: 10.1684/ejd.2014.2271
- van Loo E, Mosterd K, Krekels GAM, et al. Surgical excision versus Mohs’ micrographic surgery for basal cell carcinoma of the face: a randomised clinical trial with 10 year follow-up. Eur J Cancer. 2014;50(17):3011–3020. doi: 10.1016/j.ejca.2014.08.018
- Drucker AM, Adam GP, Rofeberg V, et al. Treatments of primary basal cell carcinoma of the skin: a systematic review and network meta-analysis. Ann Intern Med. 2018;169(7):456–466. doi: 10.7326/M18-0678
- Arits AHMM, Mosterd K, Essers BA, et al. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial. Lancet Oncol. 2013;14(7):647–654. doi: 10.1016/S1470-2045(13)70143-8
- Ruiz-Salas V, Alegre M, López-Ferrer A, et al. Vismodegib: a review. Actas Dermosifiliogr. 2014;105(8):744–751. doi: 10.1016/j.ad.2013.09.012
- Scalvenzi M, Costa C, Cappello M, et al. Reply to woltsche N. et al. Managing adverse effects by dose reduction during routine treatment of locally advanced basal cell carcinoma with the hedgehog inhibitor vismodegib: a single-centre experience. J Eur Acad Dermatol Venereol. 2019;33(4):e145–e147. doi: 10.1111/jdv.15469
- Von Hoff DD, LoRusso PM, Rudin CM, et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med. 2009;361(12):1164–1172. doi: 10.1056/NEJMoa0905360
- Sekulic A, Migden MR, Oro AE, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012;366(23):2171–2179. doi: 10.1056/NEJMoa1113713
- Tang JY, Mackay-Wiggan JM, Aszterbaum M, et al. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. N Engl J Med. 2012;366(23):2180–2188. doi: 10.1056/NEJMoa1113538
- Dréno B, Kunstfeld R, Hauschild A, et al. Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE): a randomised, regimen-controlled, double-blind, phase 2 trial. Lancet Oncol. 2017;18(3):404–412. doi: 10.1016/S1470-2045(17)30072-4
- Basset-Séguin N, Hauschild A, Kunstfeld R, et al. Vismodegib in patients with advanced basal cell carcinoma: primary analysis of STEVIE, an international, open-label trial. Eur J Cancer. 2017;86:334–348. doi: 10.1016/j.ejca.2017.08.022
- Grossmann LE, Ramelyte E, Nägeli MC, et al. Eight years of real-life experience with smoothened inhibitors in a Swiss tertiary skin referral center. Cancers (Basel). 2022;14(10):2496. doi: 10.3390/cancers14102496
- Villani A, Megna M, Fabbrocini G, et al. Long-term efficacy of vismodegib after its withdrawal and patients’ health-related quality of life using the Dermatology life quality index (DLQI). Dermatol Ther. 2019;9(4):719–724. doi: 10.1007/s13555-019-00323-4
- Ruiz-Salas V, Podlipnik S, Sandoval-Clavijo A, et al. Real-world experience with vismodegib on advanced and multiple BCCs: data from the RELIVIS study. Dermatology. 2023 May;239(5):685–693. doi: 10.1159/000530813
- Xavier C, Lopes E, Bexiga C, et al. Vismodegib for treatment of periocular basal cell carcinoma - 6-year experience from a tertiary cancer center. An Bras Dermatol. 2021;96(6):712–716. doi: 10.1016/j.abd.2021.04.012
- Villani A, Fabbrocini G, Costa C, et al. Vismodegib treatment in advanced basal cell carcinomas: real-life experience. Dermatol Ther. 2022;35(1):e15195. doi: 10.1111/dth.15195
- Ayén-Rodríguez A, Linares-González L, Llamas-Segura C, et al. Retrospective real-life data, efficacy and safety of vismodegib treatment in patients with advanced and multiple basal cell carcinoma: 3-year experience from a Spanish center. Int J Environ Res Public Health. 2023;20(10):5824. doi: 10.3390/ijerph20105824
- Scotti B, Melotti B, Baraldi C, et al. Analysis of basal cell carcinomas’ histological subtypes and relative response to vismodegib in six patients diagnosed with Gorlin-Goltz syndrome: a retrospective study. J Eur Acad Dermatol Venereol. 2023 Nov. doi:10.1111/jdv.19608.
- Scalvenzi M, Villani A, Mazzella C, et al. Vismodegib treatment in a HIV positive patient on antiretroviral therapy. Indian J Dermatol Venereol Leprol. 2018;84(6):758–760. doi: 10.4103/ijdvl.IJDVL_92_18
- Villani A, Fabbrocini G, Costa C, et al. Expert opinion on sonidegib efficacy, safety and tolerability. Expert Opin Drug Saf. 2021;20(8):877–882. doi: 10.1080/14740338.2021.1921734
- Villani A, Fabbrocini G, Costa C, et al. Sonidegib: safety and efficacy in treatment of advanced basal cell carcinoma. Dermatol Ther. 2020;10(3):401–412. doi: 10.1007/s13555-020-00378-8
- Amakye D, Jagani Z, Dorsch M. Unraveling the therapeutic potential of the hedgehog pathway in cancer. Nat Med. 2013;19(11):1410–1422. doi: 10.1038/nm.3389
- Pak E, Segal RA. Hedgehog signal transduction: key players, oncogenic drivers, and Cancer therapy. Dev Cell. 2016;38(4):333–344. doi: 10.1016/j.devcel.2016.07.026
- Rimkus TK, Carpenter RL, Qasem S, et al. Targeting the Sonic hedgehog signaling pathway: review of smoothened and GLI inhibitors. Cancers (Basel). 2016;8(2):22. doi: 10.3390/cancers8020022
- Villani A, Scalvenzi M, Micali G, et al. Efficacy and safety of sonidegib for the management of basal cell carcinoma: a drug safety evaluation. Expert Opin Drug Saf. 2023;22(7):525–531. doi: 10.1080/14740338.2023.2227089
- Sonidegib. EMA approval. [cited 2023 Sep 9]. Available from: https://www.ema.europa.eu/en/documents/product-information/odomzo-epar-product-information_en.pdf.
- Rodon J, Tawbi HA, Thomas AL, et al. A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor sonidegib (LDE225) in patients with advanced solid tumors. Clin Cancer Res An Off J Am Assoc Cancer Res. 2014;20(7):1900–1909. doi: 10.1158/1078-0432.CCR-13-1710
- Migden MR, Guminski A, Gutzmer R, et al. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. Lancet Oncol. 2015;16(6):716–728. doi: 10.1016/S1470-2045(15)70100-2
- Dummer R, Guminksi A, Gutzmer R, et al. Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase II randomized, double-blind BOLT study. Br J Dermatol. 2020;182(6):1369–1378. doi: 10.1111/bjd.18552
- Lear JT, Migden MR, Lewis KD, et al. Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study. J Eur Acad Dermatol Venereol. 2018;32(3):372–381. doi: 10.1111/jdv.14542
- Dummer R, Guminski A, Gutzmer R, et al. The 12-month analysis from basal cell carcinoma outcomes with LDE225 treatment (BOLT): a phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma. J Am Acad Dermatol. 2016;75(1):113–125.e5. doi: 10.1016/j.jaad.2016.02.1226
- Villani A, Fabbrocini G, Costa C, et al. Sonidegib efficacy and tolerability in advanced basal cell carcinoma: A single-center real-life experience. J Am Acad Dermatol. 2022;86(4):e175. doi: 10.1016/j.jaad.2021.11.041
- Moscarella E, Brancaccio G, Briatico G, et al. Management of advanced basal cell carcinoma: Real-life data with sonidegib. Dermatol Ther. 2021;34(3):e14948. doi: 10.1111/dth.14948
- Moreno-Arrones OM, Béa-Ardebol S, Mayo-Martinez F, et al. Sonidegib as a locally advanced basal cell carcinoma therapy in real-life clinical setting: a national multicentre study. Actas Dermosifiliogr. 2023;114(7):T565–T571. doi: 10.1016/j.ad.2023.06.011
- Villani A, Fabbrocini G, Micali G, et al. The efficacy of sonidegib in treating locally advanced basal cell carcinoma involving the periocular area. Dermatol Ther. 2023;13(9):2121–2126. doi: 10.1007/s13555-023-00985-1
- Mannino M, Piccerillo A, Fabbrocini G, et al. Clinical characteristics of an Italian patient population with advanced BCC and real-life evaluation of HHI safety and effectiveness. Dermatology. 2023 Jun;1–9. doi: 10.1159/000531280
- Toffoli L, Conforti C, Zelin E, et al. Locally advanced basal cell carcinoma: real-life data with sonidegib. Dermatol Ther. 2022;35(6):e15441. doi: 10.1111/dth.15441
- Villani A, Fabbrocini G, Scalvenzi M. Sonidegib treatment in patients with locally advanced basal cell carcinoma. Dermatol Ther. 2022;35(4):e15348. doi: 10.1111/dth.15348
- Nazzaro G, Benzecry V, Mattioli MA, et al. Sonidegib in locally advanced basal cell carcinoma: a monocentric retrospective experience and a review of published real-life data. Cancers (Basel). 2023;15(14):3621. doi: 10.3390/cancers15143621
- Villani A, Fabbrocini G, Costa C, et al. Patients with advanced basal cell carcinomas in treatment with sonic hedgehog inhibitors during the coronavirus disease 2019 (COVID-19) period: management and adherence to treatment. J Am Acad Dermatol. 2020;82(6):e205. doi: 10.1016/j.jaad.2020.03.057
- Paradisi A, Piccerillo A, Bocchino E, et al. Surgery after sonidegib treatment achieves complete response in locally advanced basal cell carcinoma of the face. J Dermatol. 2023 Sep. doi:10.1111/1346-8138.16970
- Villani A, Ocampo-Garza SS, Potestio L, et al. Cemiplimab for the treatment of advanced cutaneous squamous cell carcinoma. Expert Opin Drug Saf. 2022;21(1):21–29. doi: 10.1080/14740338.2022.1993819
- Cemiplimab. EMA approval. [cited 2023 Sep 9]. Available from: https://www.ema.europa.eu/en/documents/product-information/libtayo-epar-product-information_en.pdf.
- Stratigos AJ, Sekulic A, Peris K, et al. Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial. Lancet Oncol. 2021;22(6):848–857. doi: 10.1016/S1470-2045(21)00126-1
- Stratigos AJ, Sekulic A, Peris K, et al. Phase 2 open-label, multicenter, single-arm study of cemiplimab in patients with locally advanced basal cell carcinoma after hedgehog inhibitor therapy: extended follow-up. J Am Acad Dermatol. 2023 Oct. doi:10.1016/j.jaad.2023.08.111
- Epstein EH, Lear J, Saldanha G, et al. Hedge-hog pathway inhibition by topical pati- degib to reduce BCC burden in patients with basal cell nevus (Gorlin) syndrome. J Clin Oncol. 2018;36(15_Supll):e21626–e. doi: 10.1200/JCO.2018.36.15_suppl.e21626
- ClinicalTrials.gov. Clinical trial of patidegib gel 2%, 4%, and vehicle applied once or twice daily to decrease the GLI1 biomarker in sporadic nodular basal cell carcinomas (BCC). [cited 2023 Sep 9]. Available from: https://clinicaltrials.gov/study/NCT02828111?cond=basal%20cell%20carcinoma&term=patidegib&rank=1
- ClinicalTrials.gov. An study of patidegib topical gel, 2%, for the reduction of disease burden of persistently developing basal cell carcinomas in patients with non-Gorlin high frequency BCC. [cited 2023 Sep 9]. Available from: https://clinicaltrials.gov/study/NCT04155190?cond=basal%20cell%20carcinoma&term=burden%20gorlin&rank=2.
- ClinicalTrials.gov. Study of patidegib topical gel, 2%, for the reduction of disease burden of persistently developing basal cell carcinomas (BCCs) in subjects with basal cell Nevus syndrome (Gorlin syndrome). 2023 Sep 9.
- ClinicalTrials.gov. Topical itraconazole in treating patients with basal cell Cancer. [cited 2023 Sep 9]. Available from: https://clinicaltrials.gov/study/NCT02735356?cond=basal%20cell%20carcinoma&term=topical%20itraconazole&rank=1
- ClinicalTrials.gov. Topical itraconazole in the treatment of basal cell carcinoma. [cited 2023 Sep 9]. Available from: https://classic.clinicaltrials.gov/ct2/show/NCT02735356
- ClinicalTrials.gov. Open-label trial of SUBATM-Itraconazole (SUBA-Cap) in subjects with basal cell carcinoma Nevus syndrome (BCCNS). [cited 2023 Sep 9]. Available from: https://clinicaltrials.gov/study/NCT02354261
- Meyer T, Surber C, French LE, et al. Resiquimod, a topical drug for viral skin lesions and skin cancer. Expert Opin Investig Drugs. 2013;22(1):149–159. doi: 10.1517/13543784.2013.749236
- ClinicalTrials.gov. Efficacy and safety trial of topical resiquimod gel (0.06%) in patients with nodular basal cell carcinoma. [cited 2023 Sep 9]. Available from: https://clinicaltrials.gov/study/NCT01808950?cond=basal%20cell%20carcinoma&term=resiquimod&rank=1
- ClinicalTrials.gov. Study to determine the safety of two applications of PEP005 topical gel to superficial basal cell carcinoma. [cited 2023 Sep 9]. Available from: https://clinicaltrials.gov/study/NCT00108134?cond=basal%20cell%20carcinoma&term=pep005&rank=1
- ClinicalTrials.gov. Proof of concept study to access superficial basal cell carcinoma in adults. [cited 2023 Sep 9]. Available from: https://clinicaltrials.gov/study/NCT05713760?cond=basal%20cell%20carcinoma&term=proof%20of%20concep&rank=3
- ClinicalTrials.gov. A trial to evaluate the safety, local tolerability, pharmacokinetics and pharmacodynamics of LDE225 on skin basal cell carcinomas in Gorlin syndrome patients. [cited 2023 Sep 9]. Available from: https://clinicaltrials.gov/study/NCT01033019?cond=basal%20cell%20carcinoma&term=lde225&rank=2
- ClinicalTrials.gov. Topical remetinostat in treating patient with cutaneous basal cell Cancer. [cited 2023 Sep 9]. Available from: https://clinicaltrials.gov/study/NCT03180528?cond=basal%20cell%20carcinoma&term=remetinostat&rank=1
- Villani A, Potestio L, Fabbrocini G, et al. The treatment of advanced melanoma: therapeutic update. Int J Mol Sci. 2022;23(12):6388. doi: 10.3390/ijms23126388
- ClinicalTrials.gov. T-VEC in Non-melanoma Skin Cancer (20139157 T-VEC). [cited 2023 Sep 9]. Available from: https://clinicaltrials.gov/study/NCT03458117?cond=basal%20cell%20carcinoma&term=talimogene&rank=1
- ClinicalTrials.gov. Talimogene Laherparepvec and Nivolumab in treating patients with refractory lymphomas or advanced or refractory non-melanoma skin cancers. [cited 2023 Sep 9]. Available from: https://clinicaltrials.gov/study/NCT02978625?cond=basal%20cell%20carcinoma&term=talimogene&rank=2
- ClinicalTrials.gov. Dose escalation trial to evaluate dose limiting toxicity/maximum tolerated dose of microneedle arrays containing Doxorubicin (D-MNA) in basal cell carcinoma (BCC). [cited 2023 Sep 9]. Available from: https://clinicaltrials.gov/study/NCT03646188?cond=basal%20cell%20carcinoma&term=Doxorubicin&rank=1
- ClinicalTrials.gov. Placebo microneedles in healthy volunteers (part I) and efficacy/safety of Doxorubicin microneedles in basal cell Cancer subjects (part II). [cited 2023 Sep 9]. Available from: https://clinicaltrials.gov/study/NCT04928222?cond=basal%20cell%20carcinoma&term=Doxorubicin&rank=2
- Villani A, Scalvenzi M, Micali G, et al. Management of advanced invasive melanoma: new strategies. Adv Ther. 2023;40(8):3381–3394. doi: 10.1007/s12325-023-02555-5
- ClinicalTrials.gov. Intratumoral administration of daromun in non-melanoma skin cancer patients (DUNCAN). [cited 2023 Sep 9]. Available from: https://clinicaltrials.gov/study/NCT04362722?cond=basal%20cell%20carcinoma&term=Daromun%20&rank=1
- ClinicalTrials.gov. Study of ASN-002 to treat basal cell carcinomas (BCCs) in individuals with basal cell Nevus syndrome (BCNS). [cited 2023 Sep 9]. Available from: https://clinicaltrials.gov/study/NCT03208296?cond=basal%20cell%20carcinoma&term=asn-002&rank=1
- ClinicalTrials.gov. Safety and efficacy of ASN-002 combined with a hedgehog pathway inhibitor. [cited 2023 Sep 9]. Available from: https://clinicaltrials.gov/study/NCT04416516?cond=basal%20cell%20carcinoma&term=asn-002&rank=2
- ClinicalTrials.gov. A study of the efficacy and safety of ASN-002 in adult patients with low-risk nodular basal cell carcinoma (ASN-002-001). [cited 2023 Sep 9]. Available from: https://clinicaltrials.gov/study/NCT02550678?cond=basal%20cell%20carcinoma&term=asn-002&rank=3
- Bendell J, Andre V, Ho A, et al. Phase I study of LY2940680, a Smo antagonist, in patients with advanced Cancer including treatment-naïve and Previously treated basal cell carcinoma. Clin Cancer Res An Off J Am Assoc Cancer Res. 2018;24(9):2082–2091. doi: 10.1158/1078-0432.CCR-17-0723
- Ueno H, Kondo S, Yoshikawa S, et al. A phase I and pharmacokinetic study of taladegib, a smoothened inhibitor, in Japanese patients with advanced solid tumors. Invest New Drugs. 2018;36(4):647–656. doi: 10.1007/s10637-017-0544-y
- Jimeno A, Weiss GJ, Miller WHJ, et al. Phase I study of the hedgehog pathway inhibitor IPI-926 in adult patients with solid tumors. Clin Cancer Res An Off J Am Assoc Cancer Res. 2013;19(10):2766–2774. doi: 10.1158/1078-0432.CCR-12-3654
- Kim DJ, Kim J, Spaunhurst K, et al. Open-label, exploratory phase II trial of oral itraconazole for the treatment of basal cell carcinoma. J Clin Oncol Off J Am Soc Clin Oncol. 2014;32(8):745–751. doi: 10.1200/JCO.2013.49.9525
- ClinicalTrials.gov. Use of oral itraconazole in patients with locally limited basocellular carcinoma of skin. [cited 2023 Sep 9]. Available from: https://clinicaltrials.gov/study/NCT03972748?cond=basal%20cell%20carcinoma&term=itraconazole&rank=6
- ClinicalTrials.gov. Neoadjuvant-Adjuvant pembrolizumab in resectable advanced basal cell carcinoma of H&N. [cited 2023 Sep 9]. Available from: https://clinicaltrials.gov/study/NCT04323202?cond=basal%20cell%20carcinoma&term=Pembrolizumab&rank=2
- ClinicalTrials.gov. Pembrolizumab with or without vismodegib in treating metastatic or unresectable basal cell skin Cancer. [cited 2023 Sep 9]. Available from: https://clinicaltrials.gov/study/NCT02690948?cond=basal%20cell%20carcinoma&term=Pembrolizumab&rank=1
- ClinicalTrials.gov. Nivolumab with vismodegib in patients with basal cell nevus syndrome. [cited 2023 Sep 9]. Available from: https://clinicaltrials.gov/study/NCT03767439?cond=basal%20cell%20carcinoma&term=Nivolumab&rank=3
- ClinicalTrials.gov. Nivolumab alone or plus relatlimab or ipilimumab for patients with locally-advanced unresectable or metastatic basal cell carcinoma. [cited 2023 Sep 9]. Available from: https://clinicaltrials.gov/study/NCT03521830?cond=Relatlimab%20&rank=19
- ClinicalTrials.gov. Treatment duration increment and pharmacodynamic study of CX-4945 in patients with basal cell carcinoma (BCC). [cited 2023 Sep 9]. Available from: https://clinicaltrials.gov/study/NCT03897036?cond=CX-4945%20&rank=8
- Zelin E, Zalaudek I, Agozzino M, et al. Neoadjuvant therapy for non-melanoma skin Cancer: updated therapeutic approaches for basal, squamous, and merkel cell carcinoma. Curr Treat Options Oncol. 2021;22(4):35. doi: 10.1007/s11864-021-00826-3